Table 3.
KEGG pathway analysis. 93 frequent approaches of treating noninvasive and invasive BLCAs for KEGG are enhanced.
| ID | Description | Gene ratio | Bg ratio | P value | P.adjust | q value | Gene ID | Count |
|---|---|---|---|---|---|---|---|---|
| hsa05161 | Hepatitis B | 14/54 | 162/8016 | 1.74E − 12 | 3.56E − 10 | 1.45E − 10 | BCL2/JUN/CASP3/CASP8/PRKCA/FOS/IL-6/STAT1/PRKCB/BIRC5/E2F1/E2F2/CDK2/CCNA2 | 14 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 11/54 | 100/8016 | 3.99E − 11 | 4.09E − 09 | 1.66E − 09 | BCL2/JUN/CASP3/PRKCA/VEGFA/MMP2/IL-6/STAT1/F3/CCL2/PRKCB | 11 |
| hsa05167 | Kaposi sarcoma-associated herpes virus infection | 13/54 | 186/8016 | 1.79E − 10 | 1.23E − 08 | 4.97E − 09 | PTGS2/JUN/CASP3/CASP8/VEGFA/FOS/IL-6/STAT1/CXCL2/E2F1/E2F2/CALM1/PPP3CA | 13 |
| hsa04657 | IL-17 signaling pathway | 10/54 | 94/8016 | 4.73E − 10 | 2.42E − 08 | 9.83E − 09 | PTGS2/JUN/CASP3/CASP8/FOS/IL-6/MMP1/CCL2/CXCL2/IL-4 | 10 |
| hsa05163 | Human cytomegalovirus infection | 13/54 | 225/8016 | 1.90E − 09 | 7.80E − 08 | 3.16E − 08 | PTGS2/CASP3/CASP8/PRKCA/VEGFA/IL-6/CCL2/PTGER3/PRKCB/E2F1/E2F2/CALM1/PPP3CA | 13 |
| hsa04218 | Cellular senescence | 11/54 | 160/8016 | 6.48E − 09 | 2.22E − 07 | 8.99E − 08 | IL-6/CDK1/CCNB1/CHEK2/E2F1/E2F2/CDK2/CCNA2/CHEK1/CALM1/PPP3CA | 11 |
| hsa05170 | Human immunodeficiency virus 1 infection | 12/54 | 212/8016 | 1.11E − 08 | 3.24E − 07 | 1.32E − 07 | BCL2/JUN/CASP3/CASP8/PRKCA/FOS/CDK1/PRKCB/CCNB1/CHEK1/CALM1/PPP3CA | 12 |
| hsa04115 | p53 signaling pathway | 8/54 | 72/8016 | 2.13E − 08 | 5.46E − 07 | 2.21E − 07 | BCL2/CASP3/CASP8/CDK1/CCNB1/CHEK2/CDK2/CHEK1 | 8 |
| hsa04020 | Calcium signaling pathway | 11/54 | 193/8016 | 4.60E − 08 | 1.05E − 06 | 4.25E − 07 | CHRM3/CHRM2/ADRB2/ADRA1D/PRKCA/ERBB2/PTGER3/PRKCB/ERBB3/CALM1/PPP3CA | 11 |
| hsa05169 | Epstein-Barr virus infection | 11/54 | 201/8016 | 6.99E − 08 | 1.43E − 06 | 5.81E − 07 | BCL2/JUN/CASP3/CASP8/IL-6/STAT1/PSMD3/E2F1/E2F2/CDK2/CCNA2 | 11 |
| hsa05219 | Bladder cancer | 6/54 | 41/8016 | 2.64E − 07 | 4.91E − 06 | 1.99E − 06 | VEGFA/MMP2/MMP1/ERBB2/E2F1/E2F2 | 6 |
| hsa05031 | Amphetamine addiction | 7/54 | 69/8016 | 3.30E − 07 | 5.64E − 06 | 2.29E − 06 | MAOB/JUN/PRKCA/FOS/PRKCB/CALM1/PPP3CA | 7 |
| hsa04659 | Th17 cell differentiation | 8/54 | 107/8016 | 4.84E − 07 | 7.64E − 06 | 3.10E − 06 | RXRA/JUN/FOS/IL-6/STAT1/AHR/IL-4/PPP3CA | 8 |
| hsa04668 | TNF signaling pathway | 8/54 | 112/8016 | 6.89E − 07 | 9.85E − 06 | 3.99E − 06 | PTGS2/JUN/CASP3/CASP8/FOS/IL-6/CCL2/CXCL2 | 8 |
| hsa05206 | MicroRNAs in cancer | 12/54 | 310/8016 | 7.21E − 07 | 9.85E − 06 | 3.99E − 06 | PTGS2/BCL2/CASP3/PRKCA/VEGFA/TP63/ERBB2/PRKCB/CYP1B1/E2F1/E2F2/ERBB3 | 12 |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance | 7/54 | 79/8016 | 8.42E − 07 | 1.08E − 05 | 4.37E − 06 | BCL2/PRKCA/VEGFA/IL-6/ERBB2/PRKCB/ERBB3 | 7 |
| hsa04110 | Cell cycle | 8/54 | 124/8016 | 1.50E − 06 | 1.80E − 05 | 7.28E − 06 | CDK1/CCNB1/CHEK2/E2F1/E2F2/CDK2/CCNA2/CHEK1 | 8 |
| hsa05166 | Human T-cell leukemia virus 1 infection | 10/54 | 219/8016 | 1.58E − 06 | 1.80E − 05 | 7.28E − 06 | JUN/FOS/IL-6/CHEK2/E2F1/E2F2/CDK2/CCNA2/CHEK1/PPP3CA | 10 |
| hsa05222 | Small cell lung cancer | 7/54 | 92/8016 | 2.38E − 06 | 2.57E − 05 | 1.04E − 05 | PTGS2/RXRA/BCL2/CASP3/E2F1/E2F2/CDK2 | 7 |
| hsa05323 | Rheumatoid arthritis | 7/54 | 93/8016 | 2.56E − 06 | 2.62E − 05 | 1.06E − 05 | JUN/VEGFA/FOS/IL-6/MMP1/CCL2/CXCL2 | 7 |
| hsa05162 | Measles | 8/54 | 138/8016 | 3.36E − 06 | 3.28E − 05 | 1.33E − 05 | BCL2/JUN/CASP3/CASP8/FOS/IL-6/STAT1/CDK2 | 8 |
| hsa01522 | Endocrine resistance | 7/54 | 98/8016 | 3.64E − 06 | 3.39E − 05 | 1.38E − 05 | BCL2/JUN/FOS/MMP2/ERBB2/E2F1/E2F2 | 7 |
| hsa05223 | Non-small cell lung cancer | 6/54 | 66/8016 | 4.68E − 06 | 4.18E − 05 | 1.69E − 05 | RXRA/PRKCA/ERBB2/PRKCB/E2F1/E2F2 | 6 |
| hsa04625 | C-type lectin receptor signaling pathway | 7/54 | 104/8016 | 5.42E − 06 | 4.63E − 05 | 1.88E − 05 | PTGS2/JUN/CASP8/IL-6/STAT1/CALM1/PPP3CA | 7 |
| hsa01524 | Platinum drug resistance | 6/54 | 73/8016 | 8.47E − 06 | 6.94E − 05 | 2.82E − 05 | BCL2/CASP3/CASP8/ERBB2/BIRC5/TOP2A | 6 |
| hsa05140 | Leishmaniasis | 6/54 | 77/8016 | 1.16E − 05 | 9.11E − 05 | 3.69E − 05 | PTGS2/JUN/FOS/STAT1/PRKCB/IL-4 | 6 |
| hsa04970 | Salivary secretion | 6/54 | 90/8016 | 2.84E − 05 | 0.000215397 | 8.74E − 05 | CHRM3/ADRB2/ADRA1D/PRKCA/PRKCB/CALM1 | 6 |
| hsa04370 | VEGF signaling pathway | 5/54 | 59/8016 | 4.36E − 05 | 0.000319433 | 0.000129578 | PTGS2/PRKCA/VEGFA/PRKCB/PPP3CA | 5 |
| hsa04215 | Apoptosis—multiple species | 4/54 | 32/8016 | 5.75E − 05 | 0.000398847 | 0.000161792 | BCL2/CASP3/CASP8/BIRC5 | 4 |
| hsa05205 | Proteoglycans in cancer | 8/54 | 204/8016 | 5.84E − 05 | 0.000398847 | 0.000161792 | CASP3/PRKCA/VEGFA/MMP2/ERBB2/CAV1/PRKCB/ERBB3 | 8 |
| hsa04921 | Oxytocin signaling pathway | 7/54 | 153/8016 | 6.71E − 05 | 0.000444038 | 0.000180123 | PTGS2/JUN/PRKCA/FOS/PRKCB/CALM1/PPP3CA | 7 |
| hsa05160 | Hepatitis C | 7/54 | 155/8016 | 7.29E − 05 | 0.00046711 | 0.000189483 | RXRA/CASP3/CASP8/STAT1/E2F1/E2F2/CDK2 | 7 |
| hsa04066 | HIF-1 signaling pathway | 6/54 | 109/8016 | 8.37E − 05 | 0.000519791 | 0.000210852 | BCL2/PRKCA/VEGFA/IL-6/ERBB2/PRKCB | 6 |
| hsa04725 | Cholinergic synapse | 6/54 | 112/8016 | 9.73E − 05 | 0.000586899 | 0.000238075 | CHRM3/CHRM2/BCL2/PRKCA/FOS/PRKCB | 6 |
| hsa04151 | PI3K-Akt signaling pathway | 10/54 | 354/8016 | 0.000104478 | 0.000611944 | 0.000248234 | RXRA/CHRM2/BCL2/PRKCA/VEGFA/IL-6/ERBB2/ERBB3/CDK2/IL-4 | 10 |
| hsa04726 | Serotonergic synapse | 6/54 | 115/8016 | 0.000112728 | 0.000641922 | 0.000260395 | PTGS1/PTGS2/MAOB/CASP3/PRKCA/PRKCB | 6 |
| hsa05164 | Influenza A | 7/54 | 170/8016 | 0.000130414 | 0.000722567 | 0.000293108 | CASP3/CASP8/PRKCA/IL-6/STAT1/CCL2/PRKCB | 7 |
| hsa04010 | MAPK signaling pathway | 9/54 | 295/8016 | 0.000135506 | 0.00072873 | 0.000295608 | JUN/CASP3/PRKCA/VEGFA/FOS/ERBB2/PRKCB/ERBB3/PPP3CA | 9 |
| hsa05214 | Glioma | 5/54 | 75/8016 | 0.000138636 | 0.00072873 | 0.000295608 | PRKCA/PRKCB/E2F1/E2F2/CALM1 | 5 |
| hsa05133 | Pertussis | 5/54 | 76/8016 | 0.000147646 | 0.000738228 | 0.000299461 | JUN/CASP3/FOS/IL-6/CALM1 | 5 |
| hsa05212 | Pancreatic cancer | 5/54 | 76/8016 | 0.000147646 | 0.000738228 | 0.000299461 | VEGFA/STAT1/ERBB2/E2F1/E2F2 | 5 |
| hsa05152 | Tuberculosis | 7/54 | 180/8016 | 0.000186086 | 0.000908277 | 0.000368441 | BCL2/CASP3/CASP8/IL-6/STAT1/CALM1/PPP3CA | 7 |
| hsa04621 | NOD-like receptor signaling pathway | 7/54 | 181/8016 | 0.000192575 | 0.00091809 | 0.000372422 | BCL2/JUN/CASP8/IL-6/STAT1/CCL2/CXCL2 | 7 |
| hsa04114 | Oocyte meiosis | 6/54 | 128/8016 | 0.000203229 | 0.000946864 | 0.000384094 | PGR/CDK1/CCNB1/CDK2/CALM1/PPP3CA | 6 |
| hsa04926 | Relaxin signaling pathway | 6/54 | 129/8016 | 0.000212049 | 0.000966002 | 0.000391857 | JUN/PRKCA/VEGFA/FOS/MMP2/MMP1 | 6 |
| hsa04728 | Dopaminergic synapse | 6/54 | 132/8016 | 0.000240337 | 0.001071065 | 0.000434476 | MAOB/PRKCA/FOS/PRKCB/CALM1/PPP3CA | 6 |
| hsa04012 | ErbB signaling pathway | 5/54 | 85/8016 | 0.000250398 | 0.001092162 | 0.000443034 | JUN/PRKCA/ERBB2/PRKCB/ERBB3 | 5 |
| hsa05210 | Colorectal cancer | 5/54 | 86/8016 | 0.000264505 | 0.001129656 | 0.000458243 | BCL2/JUN/CASP3/FOS/BIRC5 | 5 |
| hsa04210 | Apoptosis | 6/54 | 136/8016 | 0.000282596 | 0.001182288 | 0.000479593 | BCL2/JUN/CASP3/CASP8/FOS/BIRC5 | 6 |
| hsa04915 | Estrogen signaling pathway | 6/54 | 138/8016 | 0.00030581 | 0.001253821 | 0.00050861 | PGR/BCL2/JUN/FOS/MMP2/CALM1 | 6 |
| hsa04510 | Focal adhesion | 7/54 | 199/8016 | 0.000344429 | 0.001384471 | 0.000561608 | BCL2/JUN/PRKCA/VEGFA/ERBB2/CAV1/PRKCB | 7 |
| hsa04658 | Th1 and Th2 cell differentiation | 5/54 | 92/8016 | 0.000362266 | 0.001415656 | 0.000574258 | JUN/FOS/STAT1/IL-4/PPP3CA | 5 |
| hsa05203 | Viral carcinogenesis | 7/54 | 201/8016 | 0.000365999 | 0.001415656 | 0.000574258 | JUN/CASP3/CASP8/CDK1/CDK2/CCNA2/CHEK1 | 7 |
| hsa04912 | GnRH signaling pathway | 5/54 | 93/8016 | 0.000380906 | 0.001446032 | 0.000586581 | JUN/PRKCA/MMP2/PRKCB/CALM1 | 5 |
| hsa05224 | Breast cancer | 6/54 | 147/8016 | 0.000429481 | 0.001600791 | 0.000649358 | PGR/JUN/FOS/ERBB2/E2F1/E2F2 | 6 |
| hsa05226 | Gastric cancer | 6/54 | 149/8016 | 0.000461636 | 0.001664529 | 0.000675213 | RXRA/BCL2/ERBB2/E2F1/E2F2/CDK2 | 6 |
| hsa05215 | Prostate cancer | 5/54 | 97/8016 | 0.00046282 | 0.001664529 | 0.000675213 | BCL2/ERBB2/E2F1/E2F2/CDK2 | 5 |
| hsa04923 | Regulation of lipolysis in adipocytes | 4/54 | 55/8016 | 0.000486421 | 0.001719247 | 0.000697409 | PTGS1/PTGS2/ADRB2/PTGER3 | 4 |
| hsa04914 | Progesterone-mediated oocyte maturation | 5/54 | 99/8016 | 0.000508446 | 0.001766634 | 0.000716632 | PGR/CDK1/CCNB1/CDK2/CCNA2 | 5 |
| hsa05134 | Legionellosis | 4/54 | 57/8016 | 0.000557794 | 0.001905798 | 0.000773083 | CASP3/CASP8/IL-6/CXCL2 | 4 |
| hsa05142 | Chagas disease (American trypanosomiasis) | 5/54 | 102/8016 | 0.00058314 | 0.001928126 | 0.000782141 | JUN/CASP8/FOS/IL-6/CCL2 | 5 |
| hsa05146 | Amoebiasis | 5/54 | 102/8016 | 0.00058314 | 0.001928126 | 0.000782141 | CASP3/PRKCA/IL-6/PRKCB/CXCL2 | 5 |
| hsa04620 | Toll-like receptor signaling pathway | 5/54 | 104/8016 | 0.000637332 | 0.002073857 | 0.000841257 | JUN/CASP8/FOS/IL-6/STAT1 | 5 |
| hsa04928 | Parathyroid hormone synthesis, secretion, and action | 5/54 | 106/8016 | 0.000695221 | 0.00222688 | 0.00090333 | RXRA/BCL2/PRKCA/FOS/PRKCB | 5 |
| hsa05321 | Inflammatory bowel disease (IBD) | 4/54 | 65/8016 | 0.000918763 | 0.002897638 | 0.001175422 | JUN/IL-6/STAT1/IL-4 | 4 |
| hsa04720 | Long-term potentiation | 4/54 | 67/8016 | 0.001029849 | 0.003198774 | 0.001297577 | PRKCA/PRKCB/CALM1/PPP3CA | 4 |
| hsa05165 | Human papillomavirus infection | 8/54 | 330/8016 | 0.001505195 | 0.004605448 | 0.001868192 | PTGS2/CASP3/CASP8/VEGFA/STAT1/E2F1/CDK2/CCNA2 | 8 |
| hsa04971 | Gastric acid secretion | 4/54 | 75/8016 | 0.001569477 | 0.00473151 | 0.001919329 | CHRM3/PRKCA/PRKCB/CALM1 | 4 |
| hsa04380 | Osteoclast differentiation | 5/54 | 128/8016 | 0.001623043 | 0.004822084 | 0.00195607 | JUN/PPARG/FOS/STAT1/PPP3CA | 5 |
| hsa04960 | Aldosterone-regulated sodium reabsorption | 3/54 | 37/8016 | 0.00190982 | 0.005514268 | 0.002236853 | NR3C2/PRKCA/PRKCB | 3 |
| hsa05143 | African trypanosomiasis | 3/54 | 37/8016 | 0.00190982 | 0.005514268 | 0.002236853 | PRKCA/IL-6/PRKCB | 3 |
| hsa04662 | B cell receptor signaling pathway | 4/54 | 82/8016 | 0.002181418 | 0.006210983 | 0.002519474 | JUN/FOS/PRKCB/PPP3CA | 4 |
| hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4/54 | 89/8016 | 0.002941331 | 0.008259901 | 0.003350615 | JUN/FOS/STAT1/PPP3CA | 4 |
| hsa05132 | Salmonella infection | 6/54 | 214/8016 | 0.002993412 | 0.008292561 | 0.003363863 | BCL2/JUN/CASP3/CASP8/FOS/IL-6 | 6 |
| hsa04024 | cAMP signaling pathway | 6/54 | 216/8016 | 0.003134975 | 0.008396427 | 0.003405996 | CHRM2/ADRB2/JUN/FOS/PTGER3/CALM1 | 6 |
| hsa04261 | Adrenergic signaling in cardiomyocytes | 5/54 | 149/8016 | 0.00315378 | 0.008396427 | 0.003405996 | ADRB2/ADRA1D/BCL2/PRKCA/CALM1 | 5 |
| hsa04932 | Nonalcoholic fatty liver disease (NAFLD) | 5/54 | 149/8016 | 0.00315378 | 0.008396427 | 0.003405996 | RXRA/JUN/CASP3/CASP8/IL-6 | 5 |
| hsa04713 | Circadian entrainment | 4/54 | 97/8016 | 0.004011834 | 0.010543923 | 0.004277124 | PRKCA/FOS/PRKCB/CALM1 | 4 |
| hsa05231 | Choline metabolism in cancer | 4/54 | 98/8016 | 0.004161902 | 0.010799873 | 0.00438095 | JUN/PRKCA/FOS/PRKCB | 4 |
| hsa04064 | NF-kappa B signaling pathway | 4/54 | 102/8016 | 0.004800227 | 0.012300582 | 0.00498971 | PTGS2/BCL2/PRKCB/CXCL2 | 4 |
| hsa04022 | cGMP-PKG signaling pathway | 5/54 | 167/8016 | 0.00512959 | 0.012857065 | 0.005215446 | ADRB2/ADRA1D/ADRA2A/CALM1/PPP3CA | 5 |
| hsa04660 | T cell receptor signaling pathway | 4/54 | 104/8016 | 0.005142826 | 0.012857065 | 0.005215446 | JUN/FOS/IL-4/PPP3CA | 4 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS) | 3/54 | 57/8016 | 0.006541874 | 0.01615764 | 0.006554319 | BCL2/CASP3/PPP3CA | 3 |
| hsa05145 | Toxoplasmosis | 4/54 | 112/8016 | 0.006677299 | 0.016295788 | 0.006610358 | BCL2/CASP3/CASP8/STAT1 | 4 |
| hsa05202 | Transcriptional misregulation in cancer | 5/54 | 186/8016 | 0.008035734 | 0.0193803 | 0.007861585 | RXRA/PPARG/IL-6/RUNX1T1/CCNA2 | 5 |
| hsa04919 | Thyroid hormone signaling pathway | 4/54 | 119/8016 | 0.008247201 | 0.01943306 | 0.007882987 | RXRA/PRKCA/STAT1/PRKCB | 4 |
| hsa04935 | Growth hormone synthesis, secretion, and action | 4/54 | 119/8016 | 0.008247201 | 0.01943306 | 0.007882987 | PRKCA/FOS/STAT1/PRKCB | 4 |
| hsa04152 | AMPK signaling pathway | 4/54 | 120/8016 | 0.0084896 | 0.019554697 | 0.007932329 | PPARG/ACACA/SLC2A4/CCNA2 | 4 |
| hsa05135 | Yersinia infection | 4/54 | 120/8016 | 0.0084896 | 0.019554697 | 0.007932329 | JUN/FOS/IL-6/CCL2 | 4 |
| hsa04924 | Renin secretion | 3/54 | 69/8016 | 0.011069325 | 0.025102948 | 0.010182967 | ADRB2/CALM1/PPP3CA | 3 |
| hsa05130 | Pathogenic Escherichia coli infection | 5/54 | 202/8016 | 0.011245951 | 0.025102948 | 0.010182967 | JUN/CASP3/CASP8/FOS/IL-6 | 5 |
| hsa04068 | FoxO signaling pathway | 4/54 | 131/8016 | 0.011469853 | 0.025102948 | 0.010182967 | IL-6/CCNB1/SLC2A4/CDK2 | 4 |
| hsa04650 | Natural killer cell-mediated cytotoxicity | 4/54 | 131/8016 | 0.011469853 | 0.025102948 | 0.010182967 | CASP3/PRKCA/PRKCB/PPP3CA | 4 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3/54 | 70/8016 | 0.01151062 | 0.025102948 | 0.010182967 | JUN/CASP3/CXCL2 | 3 |
| hsa04270 | Vascular smooth muscle contraction | 4/54 | 132/8016 | 0.011770178 | 0.025398806 | 0.010302982 | ADRA1D/PRKCA/PRKCB/CALM1 | 4 |
| hsa03320 | PPAR signaling pathway | 3/54 | 76/8016 | 0.014370984 | 0.030688039 | 0.01244855 | RXRA/PPARG/MMP1 | 3 |
| hsa05204 | Chemical carcinogenesis | 3/54 | 82/8016 | 0.017600508 | 0.03719695 | 0.015088878 | PTGS2/ADH1C/CYP1B1 | 3 |
| hsa04911 | Insulin secretion | 3/54 | 86/8016 | 0.019960958 | 0.041668682 | 0.016902829 | CHRM3/PRKCA/PRKCB | 3 |
| hsa04934 | Cushing syndrome | 4/54 | 155/8016 | 0.020122924 | 0.041668682 | 0.016902829 | AHR/E2F1/E2F2/CDK2 | 4 |
| hsa04540 | Gap junction | 3/54 | 88/8016 | 0.021203742 | 0.043467672 | 0.017632586 | PRKCA/CDK1/PRKCB | 3 |
| hsa04310 | Wnt signaling pathway | 4/54 | 160/8016 | 0.022321682 | 0.045306384 | 0.018378456 | JUN/PRKCA/PRKCB/PPP3CA | 4 |
| hsa04630 | JAK-STAT signaling pathway | 4/54 | 162/8016 | 0.023240916 | 0.046709685 | 0.018947703 | BCL2/IL-6/STAT1/IL-4 | 4 |
| hsa00350 | Tyrosine metabolism | 2/54 | 36/8016 | 0.024244872 | 0.048254357 | 0.019574296 | ADH1C/MAOB | 2 |